Project Details
Description
RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn,s Disease
| Status | Active |
|---|---|
| Effective start/end date | 2/1/18 → 12/31/24 |
Funding
- CELGENE CORPORATION
RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn,s Disease
- Shmidt, Eugenia (PI)
Project: Research project